麝香黄芪复方治疗急性脑梗死的疗效及对血脑屏障转运蛋白、炎性因子的影响  

Therapeutic Effect of Shexiang Huangqi Compound on Acute Cerebral Infarction and its Influence on Blood-Brain Barrier Transporter Proteins and Inflammatory Factors

作　　者：樊飞燕 陈娜[1] 行文娟 张运克[1,2] FAN Fei-yan;CHEN Na;XING Wen-juan;ZHANG Yun-ke(Henan University of Chinese Medicine,Zhengzhou Hennan 450046,China;First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhen Henan,450000,China)

机构地区：[1]河南中医药大学,河南郑州450046 [2]河南中医药大学第一附属医院,河南郑州450000

出　　处：《时珍国医国药》2023年第8期1901-1904,共4页Lishizhen Medicine and Materia Medica Research

基　　金：国家自然科学基金(81974564);中原科技创新领军人才项目(224200510027)。

摘　　要：目的基于益气活血,化痰开窍理论,探讨麝香黄芪复方治疗急性脑梗死患者的临床疗效及对血脑屏障转运蛋白、炎性因子的影响。方法选择2019年至2020年至我院就诊并且诊断为急性脑梗死的180例患者为研究对象,采用随机数字表法随机分为治疗组与对照组,每组各90例,治疗2周;两组均予西医常规治疗,治疗组加用麝香黄芪复方。对病人进行基线评估,通过观察治疗前后的NIHSS评分、BI评分、mRS评分、中医证候积分、临床有效率以及血清中血脑屏障转运蛋白和炎性因子的表达变化,探讨麝香黄芪复方对急性脑梗死患者的临床疗效及可能作用机制。结果治疗组有效率(94.44%)优于对照组(77.78%)(P<0.05);两组的NIHSS评分、mRS评分、中医证候积分均较治疗前降低,BI评分较治疗前升高,治疗组优于对照组(P<0.05);治疗后治疗组血清中P-gp含量明显低于对照组(P<0.05),OATP1A2含量明显高于对照组(P<0.05);两组NF-κB p65、TNF-α、IL-6、ICAM-1表达水平在治疗后均降低,治疗组优于对照组(P<0.05)。结论麝香黄芪复方对急性脑梗死患者有较好的临床疗效,可抑制血脑屏障外排蛋白P-gp的表达,促进转运蛋白OATP1A2的表达,减轻炎症反应,改善临床症状。Objective Based on the theory of invigorating Qi and activating blood circulation,resolving phlegm and opening the orifices,to explore the clinical efficacy of Shexiang Huangqi Compound in the treatment of patients with acute cerebral infarction and its effect on serum blood-brain barrier transporter proteins and inflammatory factors.Methods 180 patients diagnosed with acute cerebral infarction in our hospital from 2019 to 2020 were selected as the research objects.They were randomly divided into treatment group and control group by random number table method,and treated for 2 weeks;Both groups were treated with con⁃ventional western medicine,and the treatment group was treated with Shexiang Huangqi compound.The patients were evaluated at baseline.By observing the changes of NIHSS score,BI score,mRS score,TCM syndrome score,clinical efficiency and the ex⁃pression of blood brain barrier transporter and inflammatory factors in serum before and after treatment,the clinical efficacy and possible mechanism of Shexiang Huangqi compound on patients with acute cerebral infarction were discussed.Results The effec⁃tive rate of the treatment group(94.44%)was better than that of the control group(77.78%)(P<0.05);NIHSS score,mRS score and TCM syndrome score of the two groups were lower than those before treatment,and BI score was higher than those before treatment,and the treatment group was better than the control group(P<0.05);The content of P-gp in the serum of the treat⁃ment group was significantly lower than that of the control group(P<0.05),and the content of OATP1A2 was significantly high⁃er than that of the control group(P<0.05);The expression levels of NF-κB p65,TNF-α,IL-6 and ICAM-1 decreased af⁃ter treatment,and the treatment group was better than the control group(P<0.05).Conclusion Shexiang Huangqi compound has good clinical effect on patients with acute cerebral infarction.It can inhibit the expression of P-gp,promote the expression of OATP1A2,reduce the inflammatory reaction and improve the clinic

关 键 词：急性脑梗死 麝香黄芪复方 血脑屏障 转运蛋白 炎症因子 

分 类 号：R285.6[医药卫生—中药学]